478 related articles for article (PubMed ID: 26197392)
21. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
Sun DD; Lee PI
Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
[TBL] [Abstract][Full Text] [Related]
22. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
23. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
24. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
25. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.
Prasad D; Chauhan H; Atef E
J Pharm Sci; 2014 Nov; 103(11):3511-3523. PubMed ID: 25196860
[TBL] [Abstract][Full Text] [Related]
26. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Int J Pharm; 2018 Jun; 544(1):172-180. PubMed ID: 29669257
[TBL] [Abstract][Full Text] [Related]
27. Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.
Mishra J; Rades T; Löbmann K; Grohganz H
Pharmaceutics; 2018 Apr; 10(2):. PubMed ID: 29649124
[TBL] [Abstract][Full Text] [Related]
28. Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin.
Doreth M; Löbmann K; Priemel P; Grohganz H; Taylor R; Holm R; Lopez de Diego H; Rades T
Eur J Pharm Biopharm; 2018 Jan; 122():62-69. PubMed ID: 28986296
[TBL] [Abstract][Full Text] [Related]
29. Understanding Dissolution and Crystallization with Imaging: A Surface Point of View.
Novakovic D; Isomäki A; Pleunis B; Fraser-Miller SJ; Peltonen L; Laaksonen T; Strachan CJ
Mol Pharm; 2018 Nov; 15(11):5361-5373. PubMed ID: 30247922
[TBL] [Abstract][Full Text] [Related]
30. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
[TBL] [Abstract][Full Text] [Related]
31. In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - A proof of concept study.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Eur J Pharm Biopharm; 2018 Dec; 133():151-160. PubMed ID: 30339888
[TBL] [Abstract][Full Text] [Related]
32. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
Sun DD; Lee PI
J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
[TBL] [Abstract][Full Text] [Related]
33. Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations.
Ambike AA; Mahadik KR; Paradkar A
Pharm Res; 2005 Jun; 22(6):990-8. PubMed ID: 15948043
[TBL] [Abstract][Full Text] [Related]
34. Exploring the use of spray congealing to produce solid dispersions with enhanced indomethacin bioavailability: In vitro characterization and in vivo study.
Bertoni S; Albertini B; Ferraro L; Beggiato S; Dalpiaz A; Passerini N
Eur J Pharm Biopharm; 2019 Jun; 139():132-141. PubMed ID: 30910731
[TBL] [Abstract][Full Text] [Related]
35. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
36. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization.
Basavoju S; Boström D; Velaga SP
Pharm Res; 2008 Mar; 25(3):530-41. PubMed ID: 17703346
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
Sawicki E; Schellens JH; Beijnen JH; Nuijen B
Drug Dev Ind Pharm; 2017 Apr; 43(4):584-594. PubMed ID: 28010129
[TBL] [Abstract][Full Text] [Related]
38. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
39. Hot melt extrusion technology for improved dissolution, solubility and "spring-parachute" processes of amorphous self-micellizing solid dispersions containing BCS II drugs indomethacin and fenofibrate: Profiles and mechanisms.
Shi NQ; Wang SR; Zhang Y; Huo JS; Wang LN; Cai JH; Li ZQ; Xiang B; Qi XR
Eur J Pharm Sci; 2019 Mar; 130():78-90. PubMed ID: 30684657
[TBL] [Abstract][Full Text] [Related]
40. Enhanced dissolution of naproxen from pure-drug, crystalline nanoparticles: A case study formulated into spray-dried granules and compressed tablets.
Braig V; Konnerth C; Peukert W; Lee G
Int J Pharm; 2019 Jan; 554():54-60. PubMed ID: 30278257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
